US approves twice-yearly injection for HIV prevention – what you need to know about lenacapavir

By Andrew Owen, Molecular and Clinical Pharmacology, University of Liverpool

The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection against HIV infection. Administered once every six months, this new treatment marks a major advancement in expanding prevention options for people at risk of HIV infection.

Most HIV prevention drugs are daily pills (known as PrEP), which many people struggle to take regularly for various reasons,

Read complete article

~	Kazakhstan: Abused Woman Facing Murder Conspiracy Retrial

~	Human Rights Council Members Should Reject Eritrea’s Bid to End Scrutiny

~	Resurgence of Suicide Bombings in Nigeria’s Boko Haram Conflict

~	Non-traditional sports like pickleball and bouldering are helping Canadians get active this summer

~	How to deal with racism in an intimate relationship

~	Hidden gems of LGBTQ+ cinema: A League of Their Own was always queer

~	To make buy-now-pay-later fair for consumers, regulators need to understand why shoppers use it

~	How restoring river catchments can minimise drought and flood risks

~	UK plan to cut energy bills for industrial firms threatens to leave small businesses out in the cold

~	Brazil’s dangerous flirtation with counterterrorism